Marika Nestor

Key publications

Spiegelberg D, Mortensen A C, Lundsten S, Brown C J, Lane D P, Nestor M.
The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors.
Cancer Res. Sep 1;78(17):5084-5093 (2018).

Mohajershojai T, Jha P, Boström A, Frejd FY, Yazaki PJ, Nestor M.
In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of
Colorectal Cancer.
Front. Oncol., 31 March 2022.

Ingelshed K, Påvénius L, Spiegelberg D, Sohn S, Lianoudaki D, Hacheney J, Jiang L, Lama D, Kannan P, Bosdotter C, Fritz N, Karlsson M, Wermeling F, Nestor M, Lane DP, Sedimbi SK.
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy.
Cancer Res Com, 2 (9): 1075–1088. (2022).

Lundsten S, Spiegelberg D, Raval N R, Nestor M.
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE treated mice bearing neuroendocrine tumor xenografts
Eur J Nucl Med Mol Imaging. Apr;47(4):980-990 (2020).

Spiegelberg D, Abramenkovs A, Mortensen AC L, Lundsten S, Nestor M*, Stenerlöw B*.
The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach. *shared senior authorship
Scientific Reports. Apr 3;10(1):5923 (2020).

Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Ferrer Gago FJ, Hakkarainen A, Sipilä P, Häggblad M, Martens U, Lundgren B, Frigault MM, Lane DP, Swartling FJ, Uhrbom L, Nestor M, Marino S, Nelander S.
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
Cell Rep. Jul 14;32(2):107897 (2020).

Mortensen, AC, Spiegelberg D, Haylock A-K, Lundqvist H, Nestor M.
Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Int J Oncol. 2018 Jun;52(6):1875-1885 (2018).

Haylock A-K, Nilvebrant J, Mortensen A, Velikyan I, Nestor M*, Falk R*. *shared senior authorship
Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.
Oncotarget. May 18;8(39):65152-65170 (2017).

Marika Nestor

Novel cancer-targeting strategies for improved molecular radiotherapy

Molecular radiotherapy has revolutionised the treatment of several malignancies in recent years. However, treatment of solid tumours has been hampered by dose-limiting toxicities and tumour radioresistance.

The aim of our research is to develop novel radiolabelled cancer targeting agents and radio-sensitisation strategies for improved molecular cancer diagnostics and therapy. To enable this, targeting molecules towards cancer-associated targets are generated, radiolabelled and further evaluated and developed for use in precision imaging, theranostics, and molecular radiotherapy. Moreover, novel strategies to potentiate therapeutic effects of radiotherapy

Ultimately, our cancer targeting radiopharmaceuticals could be clinically applied to non-invasively characterise and image cancer cells, stratify patients, monitor treatment response, as well as for molecular radiotherapy. Moreover, radio-sensitisation strategies may be applied to improve outcomes of radiotherapy, enabling more effective radiation treatments, potentially also reducing radiation exposure and undesirable side effects in normal tissues.

In time, we hope that our research will contribute to improving radiotherapy treatment outcomes and prolong cancer patient survival.

Group members

  • Marika Nestor, Group Leader
  • Saloni Chopra, PhD student
  • Hanna Berglund, PhD student
  • Tabassom Mohajershojai, PhD student
  • Preeti Jha, Postdoctor
  • Anja Lundgren Mortensen, visiting researcher
  • Hanna Yushchyshyna, visiting researcher


Last updated: 2023-06-07

Content Responsible: David Gotthold(